SNY earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Hold, P/E 12.27. Updated 2026-07-23.
Sanofi (SNY) Research Hub
Sanofi (SNY) trades on NASDAQ, FR in the Healthcare (Drug Manufacturers - General) sector. As of 2026-09-11, shares last closed at 42.77 USD (-0.19%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 12.27, market cap 105.49B. This hub links to the full technical, earnings and options research available for SNY.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NASDAQ, FR |
| Last close | 42.77 USD (-0.19%) |
| 52-week range | 40.89 USD – 46.11 USD |
| Trend regime | Range |
| 14-day RSI | 44.1 (Bearish) |
| Trailing P/E | 12.27 |
| Market cap | 105.49B |
| Dividend yield | 5.42% |
| Next earnings | 2026-07-30 |
Available research for SNY
Covered Call on SNY: how it works, illustrative setup around the real 42.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SNY: how it works, illustrative setup around the real 42.77 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SNY: how it works, illustrative setup around the real 42.77 USD price, max profit/loss, breakeven and when to use it. Educational.
SNY technical analysis: range, last 42.77 USD, RSI 44.1, 52w range 40.89 USD–46.11 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is SNY in?
Sanofi (SNY) is classified under Healthcare (Drug Manufacturers - General), listed on NASDAQ, FR.
Is SNY in an uptrend or downtrend?
As of 2026-09-11, SNY is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SNY's trailing P/E ratio?
SNY's trailing P/E is 12.27, with a market cap of 105.49B. See the earnings research page for full valuation detail.
When does SNY next report earnings?
SNY is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of 1.09 USD.